Brightgene Bio Medical Stock Price To Sales
| 688166 Stock | 30.92 1.21 4.07% |
BrightGene Bio Medical fundamentals help investors to digest information that contributes to BrightGene Bio's financial success or failures. It also enables traders to predict the movement of BrightGene Stock. The fundamental analysis module provides a way to measure BrightGene Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BrightGene Bio stock.
BrightGene | Price To Sales |
BrightGene Bio Medical Company Price To Sales Analysis
BrightGene Bio's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current BrightGene Bio Price To Sales | 10.52 X |
Most of BrightGene Bio's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BrightGene Bio Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, BrightGene Bio Medical has a Price To Sales of 10.522 times. This is 50.83% lower than that of the Biotechnology sector and 89.31% lower than that of the Health Care industry. The price to sales for all China stocks is 7.86% higher than that of the company.
BrightGene Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BrightGene Bio's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BrightGene Bio could also be used in its relative valuation, which is a method of valuing BrightGene Bio by comparing valuation metrics of similar companies.BrightGene Bio is currently under evaluation in price to sales category among its peers.
BrightGene Fundamentals
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.0227 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 14.72 B | ||||
| Shares Outstanding | 422.47 M | ||||
| Shares Owned By Insiders | 39.34 % | ||||
| Shares Owned By Institutions | 18.13 % | ||||
| Price To Book | 5.55 X | ||||
| Price To Sales | 10.52 X | ||||
| Revenue | 1.18 B | ||||
| Gross Profit | 670.14 M | ||||
| EBITDA | 264.6 M | ||||
| Net Income | 200.58 M | ||||
| Total Debt | 156.87 M | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | 194.77 M | ||||
| Earnings Per Share | 0.45 X | ||||
| Target Price | 44.21 | ||||
| Number Of Employees | 1.16 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 13.06 B | ||||
| Total Asset | 5.03 B | ||||
| Retained Earnings | 830.44 M | ||||
| Working Capital | 917.49 M | ||||
| Net Asset | 5.03 B | ||||
| Last Dividend Paid | 0.096 |
About BrightGene Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BrightGene Bio Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BrightGene Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BrightGene Bio Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BrightGene Stock
BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.